Media headlines about Audentes Therapeutics (NASDAQ:BOLD) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Audentes Therapeutics earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.3655542938975 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Audentes Therapeutics stock opened at $31.14 on Thursday. The stock has a market cap of $1,052.92, a price-to-earnings ratio of -9.16 and a beta of 0.89. Audentes Therapeutics has a 52 week low of $13.90 and a 52 week high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.09. equities research analysts forecast that Audentes Therapeutics will post -3.43 earnings per share for the current fiscal year.
In related news, major shareholder Orbimed Advisors Llc sold 58,428 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $34.06, for a total value of $1,990,057.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,087,707 shares of company stock valued at $38,055,301. 47.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://baseballnewssource.com/2018/03/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-audentes-therapeutics-bold-stock-price/1972373.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.